“…Genetic studies have revealed this relationship among CLDN14 gen modifications, osteoporosis, and nephrolithiasis [3]. For some years, thiazides have been used for treatment of calcium lithiasis with hypercalciuria, producing excellent results [17,18]; but, it has also been observed that this therapy, although it decreases calciuria and with that the risk of nephrolithiasis formation, does not improve bone mineral density in comparison with usual supplements of calcium and vitamine D. Therefore, it is not indicated for monotherapy in patients with hypercalciuria, calcium lithiasis, and loss of bone mass [19]. The use of alendronate, nonetheless, has proven to decrease calciuria in combination with improvement in bone mineral density.…”